


STATUS OF THE CLAIMS

Claims 1 – 129. (canceled)

Claim 130 (previously presented). A benzodiazepine compound having the structure:



or its enantiomer,

wherein,

R₁ is selected from the group consisting of an aliphatic group having at least 2 carbons, a substituted aliphatic group having at least 2 Carbons, an aryl group, and a substituted aryl group;

and wherein R₂ and R₃ is independently selected from the group consisting of hydrogen, hydroxy, alkoxy, halo, amino, lower-alkyl-substituted-amino, acetylamino, hydroxyamino, an aliphatic group having 1-8 carbons and 1-20 hydrogens, aryl, and heterocyclic;

wherein R₄ is aliphatic, substituted aliphatic, aryl, substituted aryl, NH₂, or a group that participates in hydrogen bond formation;

or a pharmaceutically acceptable salt, prodrug or derivative thereof.

Claim 131. (previously presented) The compound of claim 130, wherein R₂ is hydroxy.

Claim 132. (previously presented) The compound of claim 130, wherein R₃ is a halogen.

Claim 133 (previously presented) The compound of claim 130, wherein R₂ is hydroxy and R₃ is a halogen.


Claim 134 (canceled).

Claim 135 (canceled).

Claim 136 (canceled).

Claim 137 (canceled).

Claim 138. (previously presented) The compound of Claim 130, wherein R₄ is



Claim 139. (previously presented) The compound of Claim 130, wherein said composition is a pharmaceutical composition.

Claim 140. (previously presented) The compound of Claim 139, further comprising a carrier.